This study is designed to identify the predictive biomarker for immunotherapy using patient samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.

[Sample acquisition]

• Informed consent is waived for those who agree to donate samples left over from other clinical trials or acquired for other purposes to be used for other research by the sign to master agreement in advance.
• The study will be conducted based on the purposes indicated in the master agreement signed by tissue donator [Clinical data acquisition]
• Baseline demographics: Sex, Birth date, expire date (last follow-up date for the survivals)
• Lung cancer treatment history: diagnosed date, treatment history (surgery, radiation therapy, chemotherapy, immunotherapy treatment history, and responses), general performance, metastatic sites
• Lung cancer histologic information: pathology, histologic subtype, EGFR mutation profile, ALK-rearrangement result

Inclusion Criteria:

1. aged above or equal to 18
2. Histologically confirmed lung cancer patients
3. Patient treated with immune checkpoint inhibitor

Exculsion Criteria:

NA

Total of 800 lung cancer patients treated with immune checkpoint inhibitor Study will be initiated from the date of IRB approval to Dec. 2020 for those who signed for master agreement for tissue donation for research purposes.